MTST (MetaStat) Retained Earnings: $-29.50 Mil (As of Feb. 2018)


What is MetaStat Retained Earnings?

MetaStat MTST Retained Earnings is $-29.50 Mil as of Feb. 2018.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. MetaStat's retained earnings for the quarter that ended in Feb. 2018 was $-29.50 Mil.

MetaStat's quarterly retained earnings declined from Aug. 2017 ($-27.36 Mil) to Nov. 2017 ($-28.53 Mil) and declined from Nov. 2017 ($-28.53 Mil) to Feb. 2018 ($-29.50 Mil).

MetaStat's annual retained earnings declined from Feb. 2016 ($-23.38 Mil) to Feb. 2017 ($-26.32 Mil) and declined from Feb. 2017 ($-26.32 Mil) to Feb. 2018 ($-29.50 Mil).

MetaStat  (OTCPK:MTST) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

MetaStat Retained Earnings Historical Data

* Premium members only.

The historical data trend for MetaStat's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MetaStat Retained Earnings Chart

MetaStat Annual Data
Trend Feb09 Feb10 Feb11 Feb12 Feb13 Feb14 Feb15 Feb16 Feb17 Feb18
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.73 -18.72 -23.38 -26.32 -29.50

MetaStat Quarterly Data
May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -26.32 -26.60 -27.36 -28.53 -29.50

MetaStat Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-29.50 Mil mean?
MetaStat (MTST) has a Retained Earnings of $-29.50 Mil as of Feb. 2018. Retained earnings is the amount of net income not issued to shareholders. View historical data on MetaStat and its competitors.
Is MetaStat's Retained Earnings too high?
MetaStat's current Retained Earnings is $-29.50 Mil.
How does MetaStat's Retained Earnings compare to OBMP and NSPX?
MetaStat's Retained Earnings of $-29.50 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on MetaStat and its competitors. MetaStat's current Retained Earnings is $-29.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MetaStat stock overvalued right now?
MetaStat (MTST) has a current Retained Earnings of $-29.50 Mil. The current Retained Earnings is $-29.50 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For MetaStat (MTST), the current Retained Earnings is $-29.50 Mil as of Feb. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MetaStat Business Description

Address 27 Drydock Avenue, 2nd Floor, Boston, MA, USA, 02210
MetaStat Inc is a us-based biotechnology company which focuses on discovering and developing personalized therapeutic (Rx) and diagnostic (Dx) treatment solutions for cancer patients. The company focuses on development programs of the novel therapeutic product candidates that target the Mena protein isoform whereas the Companion Diagnostics program is focused on developing companion tests to be used in combination with cancer drugs, that provide essential information for the safe and effective use of a corresponding drug or biological product to improve patient outcome. It also develops a prognostic diagnostic program which is focused on developing diagnostic tests that predict the risk of future metastasis in cancer patients following the initial treatment of their primary tumor.